Loading organizations...
Key people at Evidera.
Based in Bethesda, Maryland, Evidera is a contract research organization that provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and commercial value of biopharmaceutical, biotechnology, and medical device products. The company operates on a traditional fee-for-service model, assisting clients with market access and commercialization through real-world evidence studies, health economics modeling, and patient-reported outcomes. Operating as a subsidiary of PPD, which is now part of Thermo Fisher Scientific, the firm employs 622 dedicated employees to support medical products from early clinical development through post-launch commercialization phases. Evidera partners with all of the top 20 global biopharmaceutical firms and provides integrated scientific services to more than 250 small and mid-sized biotechnology companies. The organization was founded in 2013 when Symphony Technology Group established it as an independent entity following an acquisition from United BioSource Corporation.
Key people at Evidera.
Evidera is a leading provider of evidence-based solutions that support biopharmaceutical, biotechnology, and medical device companies in demonstrating the real-world effectiveness, safety, and value of their healthcare products. It helps clients generate the evidence needed to optimize market access and commercial potential throughout the product lifecycle, from pre-clinical development to post-launch and real-world use. Evidera serves pharmaceutical companies, payers, regulators, and healthcare providers by conducting studies such as efficacy trials, real-world evidence generation, patient-centered research, and market access consulting. Its services address critical challenges in regulatory approval, payer reimbursement, and patient access, ultimately facilitating better healthcare outcomes[1][2][3][5].
Evidera was established as part of PPD (Pharmaceutical Product Development), a global contract research organization, and has evolved over more than 35 years to focus on peri- and post-approval evidence generation. It has grown to become a specialized business unit within PPD, now part of Thermo Fisher Scientific, leveraging deep expertise in real-world evidence, health economics, and patient-centered research. The company’s founding vision centered on integrating scientific rigor with strategic consulting to meet the increasing demands of regulatory agencies and payers worldwide. Over time, Evidera expanded its capabilities to include advanced modeling, patient preference studies, and global market access strategies, partnering with top biopharma companies and hundreds of smaller biotech firms[1][2][5].
Evidera rides the growing trend of leveraging real-world evidence (RWE) and patient-centric data to meet evolving regulatory and payer requirements. As healthcare systems demand more robust proof of value beyond traditional clinical trials, Evidera’s capabilities in RWE, health economics, and patient engagement position it at the forefront of this shift. The timing is critical as regulatory agencies like the FDA and EMA increasingly emphasize patient-reported outcomes and real-world data in decision-making. Market forces such as rising healthcare costs, payer scrutiny, and the need for personalized medicine further drive demand for Evidera’s services. By enabling faster, more informed access decisions and supporting evidence-based pricing strategies, Evidera influences the broader ecosystem of drug development, reimbursement, and patient care[1][2][3][4].
Looking ahead, Evidera is poised to deepen its leadership in integrating real-world data with advanced analytics and patient insights, likely expanding its digital and AI-driven capabilities to enhance evidence generation efficiency and precision. Trends such as personalized medicine, value-based healthcare, and regulatory emphasis on patient-centric outcomes will shape its growth trajectory. Evidera’s influence may evolve from a service provider to a strategic partner that helps biopharma companies navigate increasingly complex evidence demands and market access landscapes globally. Its continued innovation in modeling, patient engagement, and payer collaboration will be key to sustaining competitive advantage and driving better patient outcomes in the evolving healthcare environment[1][2][3][4][5].
